What is Pear Therapeutics Financial Strength?
Pear Therapeutics has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Pear Therapeutics did not have earnings to cover the interest expense.
Pear Therapeutics's debt to revenue ratio for the quarter that ended in Dec. 2022 was 3.67.
As of today, Pear Therapeutics's Altman Z-Score is 0.00.
Competitive Comparison of Pear Therapeutics's Financial Strength
For the Health Information Services subindustry, Pear Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pear Therapeutics's Financial Strength Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pear Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Pear Therapeutics's Financial Strength falls into.
Pear Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Pear Therapeutics's Interest Expense for the
months ended in Dec. 2022 was $-1.89 Mil. Its Operating Income for the
months ended in Dec. 2022 was $-29.16 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $8.18 Mil.
Pear Therapeutics's Interest Coverage for the quarter that ended in Dec. 2022 is
| Pear Therapeutics did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Pear Therapeutics's Debt to Revenue Ratio for the quarter that ended in Dec. 2022 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Pear Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pear Therapeutics (Pear Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
200 State Street, 13th Floor, Boston, MA, USA, 02109
Pear Therapeutics Inc is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDTs), which use software to treat diseases directly. The company's vision is to advance healthcare through the widespread use of PDTs and to be the one-stop shop for PDTs offered by Pear and other organizations that may choose to make their products available to patients, providers, and payors via its commercial platform, known as PearConnect. It features four distinct system components, consisting of PDTs for patient use, the PearMD Clinician Dashboard, an end-to-end patient service center, and a data analytics system configured to aggregate patient engagement, adherence, and clinical outcome data.
Executives
| 5am Partners Iv, Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Erin K. Brenner |
officer: Chief Product Dev. Officer |
C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109 |
| Julia Strandberg |
officer: Chief Commercial Officer |
C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109 |
| Ronan O'brien |
officer: General Counsel & Secretary |
C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109 |
| Mccann Corey |
director, officer: President and CEO |
C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109 |
| Yuri Maricich |
officer: Chief Medical Officer |
C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109 |
| Ellen Snow |
officer: Chief Accounting Officer |
C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109 |
| Christopherd T Guiffre |
officer: CFO, COO, Treas., & Asst. Sec. |
65 HAYDEN AVE, LEXINGTON MA 02421 |
| Katherine Jeffery |
officer: Chief People Officer |
C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109 |
| Paul Mango |
director |
C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109 |
| Timothy A Wicks |
director |
C/O PRECISION CASTPARTS CORP., 4650 SW MACADAM AVENUE, SUITE 400, PORTLAND OR 97239 |
| Shivakumar Rajaraman |
director |
6260 LOOKOUT ROAD, BOULDER CO 80301 |
| Klp Spac 1 Llc |
10 percent owner |
195 CHURCH STREET , 15TH FLOOR, NEW HAVEN CT 06510 |
| Zack Lynch |
director |
C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109 |
| Elbrus Investments Pte. Ltd. |
10 percent owner |
60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891 |
Pear Therapeutics (Pear Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PEARQ has been successfully added to your